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decreases IgE to Ara h 2 and
Ara h 6 but does not enhance
sensitization to cross-reactive
allergensTo the Editor:
Oral immunotherapy (OIT) induces specific IgG4 antibodies
and regulatory T cells and leads to suppression of IgE-mediated
reactions.1 In pollen immunotherapy, specific IgE levels to pollen
allergens decrease with increasing IgG4.
2,3 We aimed to study
whether peanut OIT would induce neosensitization or affect
cross-reactive proteins by analyzing IgE sensitization profiles
using microarrays. In addition, we analyzed IgG4-IgE ratios to
peanut allergens during OITand assessed whether the cumulative
protein dose ingested during treatment determines the changes in
IgG4/IgE.
Fifty-eight 6- to 18-year-old children and adolescents having
moderate-to-severe peanut allergy participated in the study. The
diagnosis was based on a double-blind placebo-controlled
peanut challenge (n 5 52) or serum IgE to Ara h 2 above 25 kU/
L (27.8-365 kU/L) (n 5 6). Thirty-nine patients received peanut
OIT, whereas 19 patients continued to avoid peanuts. During
8 months, the daily peanut protein intake increased from 0.1 to
800 mg, after which patients ingested 4 peanuts daily. During the
first 19 build-up weeks, the patients used roasted defatted peanut
flour (Byrd Mill, Ashland, Va), which showed 100% allergen
activity of Ara h 1, 2, 3, and 6, 30% of Ara h 8, but lack of (<20%)
Ara h 9 activity in Immuno Solid-phase Allergen Chip
(ImmunoCAP ISAC, Thermo Fisher Scientific, Uppsala, Sweden)
inhibition assay.4 From week 20 on, the patients consumed
whole peanuts. Serum samples were drawn at baseline and after
build-up.
We measured serum IgE to 112 allergen components using the
ISAC with a detection limit of 0.3 ISAC standardized units for
specific IgE (ISU-E). We measured IgE to hazelnut Cor a 14
and cashew Ana o 3, and IgE and IgG4 to whole peanut extract,
Ara h 1, 2, 3, 8, and 9, using ImmunoCAP (Thermo Fisher
Scientific). IgE and IgG4 to Ara h 6 were measured using an
experimental ImmunoCAP test. Sensitization was defined as
>_0.3 ISU-E. The ethics committee at the Helsinki University
Hospital approved the study protocol. Patients and 1 of their
parents provided informed written consent. Data analysis
protocols can be found in the Online Repository (available at
www.jacionline.org).
At baseline, all 58 patients were sensitized to Ara h 2 (97%)
and/or Ara h 6 (98%). In addition, the majority was sensitized to
Ara h 1 (74%), Ara h 3 (70%), or Ara h 8 (79%), but only 9%were
sensitized to Ara h 9. Sensitization to any Ara h 8–cross-reactive
pathogenesis-related proteins group 10 (PR-10) protein occurred
FIG 1. Serum peanut allergen-specific IgE measured with ISAC microarray before and after peanut OIT
build-up phase. *Omitted from microarray data analysis. Only allergens with >_50% 1 1 patients sensitized
(>_0.3 ISU-E) in >_1of 4 groups (OIT pre, OIT post, avoidance pre, avoidance post) are included in order to
ensure the representativeness of the given allergen. See the Methods in this article’s Online Repository
(available at www.jacionline.org).
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Online Repository at www.jacionline.org).
Of the 39OIT patients, 34 achieved themaintenance dose and 4
patients discontinued treatment because of side effects and 1 for
nonmedical reasons. In the avoidance group, 6 of 19
experienced a single accidental exposure to a peanut or an
unknown nut.
Specific IgE to Ara h 2 and 6, which are the best markers of
severe peanut allergy,4 decreased significantly from median 39
ISU-E (range, 1.0-176) to 6 ISU-E (range, 1.2-86) and from 35
ISU-E (range, 1.4-157) to 4.9 ISU-E (range, 1.0-37)
(P < .0001), respectively, during OIT. No significant changes
occurred in specific IgE to Ara h 1, 3, 8, or 9 (Fig 1). The
dominance of serological response to Ara h 2 over Ara h 1 and
3 in peanut OIT has been observed in previous studies in children
and adolescents.5,6 OIT did not affect specific IgE to other 2S
albumins Ber e 1, Ses i 1, Fag e 2, Jug r 1 (ISAC microarray),
Cor a 14, or Ana o 3 (ImmunoCAP) (data not shown). PR-10,
lipid transfer protein, and profilin allergen families were
unaffected (see Table E2 in this article’s Online Repository at
www.jacionline.org). Thus, peanut OIT had no effect on specific
IgE levels of other 2S albumins, and neosensitization to these
allergens did not occur. As specific IgE to hazelnut and cashew
2S albumins were unaffected, the treatment modifies only peanut
allergy despite the cosensitization to other nuts. Despite the expo-
sure to Ara h 8 during OIT, our patients showed no changes in the
levels of IgE to Ara h 8, Bet v 1, or other PR-10 proteins. This
might be because, despite Ara h 8 retaining some activity inroasted products, its amount is small and it is degraded in the
gastrointestinal tract. Or, sensitization to Ara h 8 is mainly driven
by Bet v 1 and therefore OIT seems not to affect IgE responses to
Ara h 8. This is supported by the fact that in contrast to peanut
OIT, subcutaneous birch-pollen immunotherapy may decrease
IgE to cross-reactive PR-10 proteins.2
We observed no neosensitizations to Ara h 9 or other lipid
transfer proteins, thoughAra h 9 content is low in peanuts7 as well
as it was in roasted peanut flour4 despite its heat stability.
Specific IgG4 to Ara h 1, 2, 3, 6, 8, 9, and whole peanut extract
were low at baseline but increased significantly—except for Ara h
8 and 9—during OIT (see Table E3 and Fig E2 in this article’s
Online Repository at www.jacionline.org). IgG4-IgE ratios for
Ara h 1, 2, 3, 6, and whole peanut extract increased significantly,
whereas those for Ara h 8 and 9 remained stable (Fig 2). The
increase in IgG4-IgE correlated with the cumulative amount of
peanut protein ingested during OIT. The strongest correlations
were observed for Ara h 2 (Spearman r 5 0.50, P 5 .001), Ara
h 6 (r 5 0.36, P 5 .026) (n 5 38), Ara h 3 (r 5 0.43,
P5.007), andwhole peanut extract (r5 0.47,P5.002). In sensi-
tized individuals, a high peanut-specific IgG4-IgE ratio predicts
tolerance.8,9 The infrequent sensitization to Ara h 9 at
baseline might explain why peanut OIT lacked an effect on the
Ara h 9–specific IgG4-IgE ratio, because pretreatment IgE
response to a specific allergen seems to be necessary for the
induction of IgG4 antibodies by immunotherapy.
3 However,
unaffected IgG4-IgE ratio for Ara h 8 cannot be explained by
low pretreatment IgE response, as the majority of our patients
FIG 2. IgG4-IgE ratios to peanut allergens and whole peanut extract measured with ImmunoCAP before and
after peanut OIT build-up phase.
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to Ara h 1, 2, 3, 6, and whole peanut extract increased more in
patients who ingested larger cumulative allergen dose; thus, the
ratio may function as a proxy for success in OIT.
In conclusion, during peanut OIT, the serological response is
directed to the peanut storage proteins, and especially, to the
2S albumins. No neosensitization to cross-reactive allergens
emerges.
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stimulator of interferon genes
(STING)–associated vasculopathy
with onset in infancy caused
by 2 de novo variants in TMEM173To the Editor:
Stimulator of interferon genes (STING), which is encoded by
transmembrane protein 173 (TMEM173), is an important
mediator in initiating innate immune responses by detecting
aberrant DNA species or cyclic di-GMP-AMP (cGAMP) in the
cytosol and driving synthesis of type I interferon.1-3 cGAMP
molecules, which are produced by cyclic GMP-AMP synthase,
bind to STING homodimers embedded in the endoplasmic
reticulum membrane and eventually cause phosphorylation of
interferon regulatory factor 3 by activating Tank-binding
kinase 1 (TBK1). Patients with activating mutations of STING
display early onset of chronic inflammation and vasculopathy
caused by increased type I interferon signaling, a condition
termed STING-associated vasculopathy with onset in infancy
(SAVI).2,3 Improved understanding of STING’s function and its
implications in disease pathogenesis has suggested new potential
avenues of disease treatment options through modulating STING
signaling pathway components.
A 9-year-old Korean boy presented with systemic
hyperinflammatory symptoms, including skin lesions, brain
infarctions, and pulmonary dysfunction. From 6 months of age,
he experienced recurrent infections, including acute otitis media,
pneumonia, and gastroenteritis. Telangiectatic skin mottling on
both the hands and feet was evident from 12months of age, which
progressed to the extremities and face over time (Fig 1, A, and see
Fig E1 in this article’s Online Repository at www.jacionline.org).
At 5 years of age, he was hospitalized because of pneumococcal
meningitis, and brain magnetic resonance imaging and magnetic
resonance angiography revealed evidence of infarction in the
right parietal area. Chest computed tomography at 8 years of
age showed evidence of obliterative bronchiolitis with
peribronchial inflammation (Fig 1, B). Consequently, the patient 2016 The Authors. Published by Elsevier, Inc. on behalf of the American Academy of
Allergy, Asthma & Immunology. This is an open access article under the CC BY-NC-
ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).experienced sudden left leg weakness and headache. Brain
magnetic resonance imaging revealed acute infarction in the right
anterior watershed area and subarachnoid hemorrhages, and
magnetic resonance angiography showed diffuse advanced
luminal irregularities throughout the cerebral arteries (Fig 1, C).
At 9 years of age, a low nasal bridge was apparent and likely
caused by a perforated nasal septum (Fig 1, D). Generalized
telangiectatic rashes on the cheeks, nose, arms, legs, hands, and
feet, with gangrenous lesions, were associated with his
recurrent infections. He had slight dyspnea, which worsened on
physical exertion but needed continuous supplemental oxygen
of 1 L/min or more to maintain an oxygen saturation measured
by pulse oximetry of between 90% and 95%. Wheezing and
crackles were audible in both lower lung fields.
Trio-based whole-exome sequencing was performed (Fig 1, E,
and see Table E1 in this article’s Online Repository at www.
jacionline.org) to search for variants that were specifically found
in the patient. Among the candidates, 2 de novo variants of
TMEM173 appeared to be the most promising based on known
disease associations with the patient’s phenotype (Fig 1, F, and
see Table E2 and Figs E2 and E3 in this article’s Online
Repository at www.jacionline.org). To determine whether the 2
variants occurred in the same chromosome (in cis) or on different
chromosomes (in trans), we amplified a 3.8-kb fragment of
TMEM173 that encompasses both variants, sequenced it using
the PacBio sequencing platform, and found that both variants
occurred in the paternal chromosome (see Fig E2).
The variants were not observed in any of the public (1000
Genomes and ExAC) or private (1060 healthy Koreans)
databases, and the corresponding amino acid residues are strongly
conserved among vertebrate orthologs (Fig 1, G). The changes
were predicted to be damaging by using variant effect prediction
software, and the amino acids are located on the transmembrane
(p.Ser102Pro) and cytoplasmic domains (p.Phe279Leu), which
are involved in homodimerization and are distant from previously
reported pathogenic mutations on exon 5 (Fig 1,H, and see Tables
E2 and E3 in this article’s Online Repository at www.jacionline.
org). Analysis of the protein structure reveals that Phe279 is
located on the N-terminus of the fourth a-helix, which converges
physically with the N-terminus of the first a-helix, possibly
affecting nearby amino acids, including Asn154 and Val155,
which were found to be mutated in patients with SAVI (Fig 1,
I). Analysis of Ser102 was unavailable, although a recent study
suggests that Ser103 is important for maintaining proper
subcellular localization.4
Based on the known functions of STING, we investigated
further the functional consequences of the STING variants. First,
patient-derived fibroblasts displayed increased expression of
IFN-b, helping to explain the increased inflammatory responses
in the patient (Fig 2, A). To understand the molecular basis for
increased IFN-b expression, we monitored IFN-b promoter
activity by expressing the various mutant STING proteins in
HEK293T cells (Fig 2, B). As the cGAMP concentration
increases, cells expressing the mutant STING proteins had
increased IFN-b promoter activity compared with cells
expressing the wild-type STING but with 2 notable differences
from previous observations. First, the double-mutant STING
(S102P 1 F279L) showed stronger activity than the STING
with a single mutation (S102P or F279L), implying an additive
mode of action by the 2 variants. Second, at a baseline level,
the mutant STING proteins barely displayed any IFN-b promoter
METHODS
Statistical analysis
We filtered the ISAC microarray data so that the measured value of an
allergen had to be above the detection limit (0.3 ISU-E) in >_50% 1 1 of the
individuals in >_1experimental group (OIT group pre, OIT group post,
avoidance group pre, or avoidance group post) in order for the allergen to
be considered representative and included in the analysis. We fitted a linear
model to investigate the effects of treatment, response, subject, sex, age, and
season. Furthermore, we used the eBayes test for pairwise comparisons of
interest. P values were corrected in each pairwise comparison by using the
Benjamini-Hochberg procedure.E1
For analyses other than that of ISAC microarray data, we used Fisher exact
test and the Mann-Whitney U test for comparing 2 groups and the Wilcoxon
signed rank test for comparing repeated measurements. For the IgG4-IgE
ratios, IgE was converted to mg/L with a conversion factor of
1 kU/L 5 0.0024 mg/L.E2
We used R software, version 3.0 (R Project for Statistical Computing,
R Foundation, Vienna, Austria; http://www.r-project.org/) with limma
packageE3 and IBM SPSS Statistics 22 (IBM, Armonk, NY).
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FIG E1. Sensitization prevalences (%) to individual allergens in protein
families cross-reactive to peanut.
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FIG E2. Changes in the levels of specific IgG4 to Ara h 2, Ara h 6, and whole peanut extract measured with
ImmunoCAP in (A) OIT group and (B) avoidance group before and after peanut OIT build-up phase.
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TABLE E1. Baseline characteristics of the patients in the OIT and avoidance groups
OIT n5 39 Avoidance n 5 19 P value
Male, n (%) 22 (56) 12 (63) .78
Age (y), median (range) 8.3 (6.3-18.6) 8.6 (6.0-13.7) .97
S-IgE (kU/L), median (range) 676 (95-4458) 759 (116-11182) .46
Time from baseline blood sample to end-of study blood sample (mo), median (range) 16 (4-28) 19 (11-31) .01
Cumulative dose of peanut protein (g), mean (95% CI) 77 (65-90) 0 (0) <.001
Peanut IgE ImmunoCAP (kU/L), median (range) 75 (1.8-1820) 66 (0.9-876) .57
Ara h 2 IgE ImmunoCAP (kU/L), median (range) 44 (0.6-699) 32 (1.0-365) .49
Ara h 6 IgE ImmunoCAP (kU/L), median (range) 36 (0.3-354)* 22 (0.8-441) .78
*n 5 38.
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TABLE E2. Specific IgE levels measured with ISAC microarray
Specific IgE (ISU-E)











Ara h 2 39 0.3-175 5.0 0.3-85 <.0001 <.0001 30 0.3-148 22 0.84-174 .95 .95
Ara h 6 34 0.41-157 3.9 0.3-36 <.0001 <.0001 21 0.3-154 21 0.40-163 .61 .95
Ber e 1 0.3 0.3-1.0 0.3 0.3-2.0 — — 0.3 0.3-0.4 0.3 0.3-1.5 — —
Fag e 2 0.3 0.3-0.3 0.3 0.3-0.3 — — 0.3 0.3-0.3 0.3 0.3-0.3 — —
Jug r 1 0.3 0.3-24 0.3 0.3-62 — — 0.3 0.3-86 0.3 0.3-45 — —
Ses i 1 0.3 0.3-3.1 0.3 0.3-2.5 — — 0.3 0.3-2.4 0.3 0.3-1.7 — —
7S globulins
Ara h 1 19 0.3-146 5.8 0.3-65 .04 .25 9.0 0.3-100 5.5 0.3-118 .93 .95
Gly m 5 0.3 0.3-26 0.3 0.3-35 — — 0.3 0.3-27 0.3 0.3-35 — —
Jug r 2 0.3 0.3-4.6 0.3 0.3-6.2 — — 0.3 0.3-3.2 0.3 0.3-2.8 — —
11S globulins
Ana o 2 0.3 0.3-6.8 0.3 0.3-14 — — 0.3 0.3-4.2 0.3 0.3-11 — —
Ara h 3 2.8 0.3-104 1.8 0.3-71 .33 .99 1.1 0.3-20 0.7 0.3-23 .80 .95
Cor a 9 0.3 0.3-6.8 0.3 0.3-7.2 — — 0.3 0.3-2.3 0.3 0.3-124 — —
Gly m 6 0.6 0.3-51 0.6 0.3-50 .85 .99 0.6 0.3-12 0.5 0.3-27 .76 .95
LTP
Ara h 9 0.3 0.3-8.9 0.3 0.3-27 — — 0.3 0.3-4.7 0.3 0.3-8.6 — —
Art v 3 0.3 0.3-3.2 0.3 0.3-5.6 — — 0.3 0.3-2.9 0.3 0.3-3.3 — —
Cor a 8 0.3 0.3-1.5 0.3 0.3-5.4 — — 0.3 0.3-0.7 0.3 0.3-15 — —
Jug r 3 0.3 0.3-3.7 0.3 0.3-7.8 — — 0.3 0.3-2.4 0.3 0.3-4.4 — —
Ole e 7 0.3 0.3-1.1 0.3 0.3-8.8 — — 0.3 0.3-1.7 0.3 0.3-0.3 — —
Par j 2 0.3 0.3-1.0 0.3 0.3-0.4 — — 0.3 0.3-2.1 0.3 0.3-31 — —
Pla a 3 0.3 0.3-2.2 0.3 0.3-6.9 — — 0.3 0.3-3.8 0.3 0.3-5.1 — —
Pru p 3 0.3 0.3-2.8 0.3 0.3-7.0 — — 0.3 0.3-2.6 0.3 0.3-17 — —
Tri a 14 0.3 0.3-2.2 0.3 0.3-1.7 — — 0.3 0.3-38 0.3 0.3-103 — —
PR-10
Act d 8 0.3 0.3-13 0.3 0.3-29 — — 0.3 0.3-29 0.3 0.3-60 — —
Aln g 1 12 0.3-158 9.4 0.3-83 .60 .99 9.7 0.3-140 4.6 0.3-72 .31 .95
Api g 1 0.3 0.3-22 0.3 0.3-21 — — 0.3 0.3-2.7 0.3 0.3-30 — —
Ara h 8 4.6 0.3-97 3.1 0.3-82 .43 .99 4.5 0.3-77 1.5 0.3-85 .42 .95
Bet v 1 48 0.3-163 37 0.3-162 .64 .99 56 0.3-175 46 0.3-176 .67 .95
Cor a 1.0101 4.6 0.3-77 4.1 0.3-50 .73 .99 2.5 0.3-91 2.2 0.3-79 .46 .95
Cor a 1.0401 11 0.3-128 9.1 0.3-59 .99 .99 7.2 0.3-112 6.8 0.3-99 .80 .95
Gly m 4 0.9 0.3-87 1.2 0.3-62 .88 .99 0.5 0.3-75 0.6 0.3-38 .84 .95
Mal d 1 14 0.3-157 9.7 0.3-130 .58 .99 14 0.3-150 9.2 0.3-160 .50 .95
Pru p 1 7.9 0.3-126 7.2 0.3-103 .68 .99 6.9 0.3-136 2.6 0.3-157 .41 .95
Profilins
Bet v 2 0.3 0.3-86 0.3 0.3-22 — — 0.3 0.3-52 0.3 0.3-66 — —
Hev b 8 0.3 0.3-121 0.3 0.3-35 — — 0.3 0.3-69 0.3 0.3-85 — —
Mer a 1 0.3 0.3-82 0.3 0.3-18 — — 0.3 0.3-54 0.3 0.3-90 — —
Phl p 12 0.3 0.3-26 0.3 0.3-7.5 — — 0.3 0.3-5.2 0.3 0.3-22 — —
Grass group 1
Phl p 1 1.6 0.3-131 1.6 0.3-162 .93 .99 4.4 0.3-141 5.5 0.3-115 .92 .95
Values are presented as median, range. —, Omitted from microarray data analysis. Only allergens with >_50% 1 1 patients sensitized (>_0.3 ISU-E) in >_1of 4 groups (OIT pre, OIT
post, avoidance pre, avoidance post) are included in order to ensure the representativeness of the given allergen.
LTP, Lipid transfer protein.
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TABLE E3. Changes in levels of specific IgG4 in the OIT and avoidance groups measured with ImmunoCAP
Specific IgG4
OIT n 5 39 Avoidance n 5 19
Baseline Post P value Baseline Post P value
Peanut 0.83 (<0.07-32.8) 11.3 (0.57-291) <.001 0.59 (0.09-9.64) 0.71 (0.09-5.12) .22
Ara h 1 0.07 (<0.07-0.92) 1.28 (<0.07-16.6) <.001 0.07 (<0.07-4.14) 0.07 (<0.07-1.74) .12
Ara h 2 0.13 (<0.07-3.72) 4.73 (<0.07-250) <.001 0.19 (<0.07-1.00) 0.11 (<0.07-0.98) .21
Ara h 3 0.07 (<0.07-7.03) 0.34 (<0.07-21.3) <.001 0.07 (<0.07-6.94) 0.07 (<0.07-2.19) .03
Ara h 6* 0.09 (<0.07-1.91) 9.11 (<0.07-134) <.001 0.14 (<0.07-1.35) 0.15 (<0.07-1.94) .84
Ara h 8 0.07 (<0.07-2.55) 0.18 (<0.07-6.32) .006 0.07 (<0.07-1.51) 0.07 (<0.07-0.35) .37
Ara h 9 0.09 (<0.07-14.1) 0.13 (<0.07-70.1) .12 0.07 (<0.07-2.35) 0.07 (<0.07-2.32) .67
Boldface P values are statistically significant.
Values are presented in mg/L as median (range).
*n 5 38 and 19.
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